1. Clinical & Scientific Overview
Nortriptyline & Clomipramine Hydrochloride (TIP-MED-000453, Reference Code [11.16]) is classified under
Neurology Medicines as a Secondary & Tertiary Amine Tricyclic Antidepressants — TCAs (Schedule H | NLEM 2022 [Clomipramine]).
Within the Indian regulatory and compendial framework, it is governed under Schedule H1 (Rx — 3-Year Register Retention & Red-Border Warning).
Representative Indian Formulations (for identification only): Nortriptyline: Sensival (Wallace), Primox (Sun); FDCs with Pregabalin/Gabapentin + Methylcobalamin (Pregabalin-NT, Gabapin-NT). | Strengths: Nortriptyline Tablets: 10 mg, 25 mg. Clomipramine Tablets/Capsules: 10 mg, 25 mg, 50 mg, 75 mg SR
Standard hospital formulary strengths
3. Mechanism of Action & Pharmacodynamics
Established pharmacological class action (Secondary & Tertiary Amine Tricyclic Antidepressants — TCAs (Schedule H | NLEM 2022 [Clomipramine])): targets primary receptor, enzyme, ion-channel, or cellular pathway to achieve therapeutic efficacy in Nortriptyline: Neuropathic pain (diabetic neuropathy, post-herpetic neuralgia, trigeminal neuralgia), migraine prophylaxis, and depression (Nortriptyline is the active demethylated metabolite of Amitriptyline and causes ~40% less M1 anticholinergic, H1 sedative, and alpha-1 orthostatic toxicity than Amitriptyline!).
4. Therapeutic Indications & Evidence-Supported Uses
- Nortriptyline: Neuropathic pain (diabetic neuropathy, post-herpetic neuralgia, trigeminal neuralgia), migraine prophylaxis, and depression (Nortriptyline is the active demethylated metabolite of Amitriptyline and causes ~40% less M1 anticholinergic, H1 sedative, and alpha-1 orthostatic toxicity than Amitriptyline!)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Nortriptyline (Neuropathic Pain / Migraine): Start 10 mg PO at bedtime (1–2 hours before sleep), titrate every 1–2 weeks to 25–50 mg HS (Depression: up to 75–100 mg/d). (Duration: Neuropathic pain/Migraine: 3–6+ months. OCD: >=12 months; taper gradually over 4 weeks when stopping)
Administration & Meal Timing: Oral (PO) | Food & Meal Timing: Take at BEDTIME (or 1–2 hours before desired sleep time to reduce morning hangover drowsiness); take Clomipramine with food to reduce GI nausea | Best Time of Day: Bedtime / Evening (8:00–9:00 PM)
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Hospital pharmacokinetic profile; monitor therapeutic response and organ clearance.
Renal: Hydroxylated active metabolites (10-OH-nortriptyline) accumulate in CKD Stage 4–5 — use lowest dose (10 mg HS). Hepatic: Reduce dose by 50% in hepatic impairment
Renal: Hydroxylated active metabolites (10-OH-nortriptyline) accumulate in CKD Stage 4–5 — use lowest dose (10 mg HS). Hepatic: Reduce dose by 50% in hepatic impairment
Renal: Hydroxylated active metabolites (10-OH-nortriptyline) accumulate in CKD Stage 4–5 — use lowest dose (10 mg HS). Hepatic: Reduce dose by 50% in hepatic impairment
7. Contraindications, Precautions & High-Risk Warnings
- CONTRAINDICATED in recent myocardial infarction, bundle-branch / AV heart block, QTc prolongation, narrow-angle glaucoma, severe urinary retention (BPH), Child–Pugh C liver failure, and within 14 days of MAO inhibitors (Linezolid, Selegiline — fatal Serotonin Syndrome!)
Key Clinical Precautions: High-alert hospital specialist agent; administer under close physiological and laboratory monitoring.
8. Adverse Effects Profile
- Dry mouth, constipation, blurred vision, drowsiness, weight gain, orthostatic dizziness, sinus tachycardia, sexual dysfunction, sweating (Clomipramine > Nortriptyline)
- Monitor for hemodynamic instability, organ toxicity, or severe hypersensitivity.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- POTENT CYP2D6 INHIBITORS (Fluoxetine, Paroxetine, Bupropion, Terbinafine, Duloxetine, Quinidine, Cimetidine) increase Nortriptyline and Clomipramine plasma levels 3–5-fold -> acute TCA cardiotoxicity!
- Fluvoxamine (CYP1A2/2C19 inhibitor) quadruples Clomipramine levels!
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Continuous clinical, hemodynamic, and organ-function laboratory monitoring.
Pharmacist Patient Counselling Points:
- COUNTER DUPLICATION CHECK: Many Indian neuropathy prescriptions combine 'Gabapin-NT' or 'Pregabalin-NT' (which ALREADY contain Nortriptyline 10 mg!) with a separate 'Sensival' or 'Tryptomer' tablet — always check FDC compositions to prevent double TCA dosing! Take 1–2 hours before bedtime so morning drowsiness wears off before waking
Storage, Stability & Dispensing Safeguards: Store in original moisture-protected packaging below 25°C–30°C (or 2°C–8°C cold chain if parenteral/biological vial specified in strengths: Nortriptyline Tablets: 10 mg, 25 mg. Clomipramine Tablets/Capsules: 10 mg, 25 mg, 50 mg, 75 mg SR). Missed-Dose Rule: Take at bedtime if remembered; skip if not remembered until the next morning (taking in the morning causes severe daytime sedation)
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO • NCBI Bookshelf
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [11.23] Trihexyphenidyl (Benzhexol) Hydrochloride — Centrally Acting Antimuscarinic (M1) Anticholinergic for Drug-Ind
- [11.28] Sumatriptan, Rizatriptan & Betahistine / Cinnarizine / Flunarizine — 5-HT1B/1D Receptor Agonist Acute Migraine Triptans & Vestibular/M
- [3.1] Amlodipine (as Amlodipine Besylate) — Dihydropyridine Calcium Channel Blocker (CCB); Arterial Vasodilat
- [11.18] Etizolam, Chlordiazepoxide & Clobazam — Thienodiazepine, Long-Acting 1,4-Benzodiazepine & 1,5-Benzodiazep